Lipella Pharmaceuticals
LIPO
LIPO was delisted on the 18th of June, 2025.
2 hedge funds and large institutions have $44.7K invested in Lipella Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.03% more ownership
Funds ownership: 0% → 0.03% (+0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$47.7K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$6.01K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Citadel Advisors
Miami,
Florida
| $39.8K | +$47.7K | +1,564 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $4.94K | +$6.01K | +197 | New |
|
LIPO Hedge Fund Activity: Q4 2022 in Review
2 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Lipella Pharmaceuticals (LIPO) for Q4 2022, worth a combined $44.7K.
Buyers outnumbered sellers: 2 funds opened new LIPO positions and 0 closed out — a net gain of 2 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $47.7K.
- 2 institutional investors held Lipella Pharmaceuticals (LIPO) as of Q4 2022, up from 0 in Q3 2022.
- Funds reported $44.7K of Lipella Pharmaceuticals stock for Q4 2022.
- 2 funds opened new Lipella Pharmaceuticals positions in Q4 2022 and 0 closed out, a net change of +2 holders.
- The largest Lipella Pharmaceuticals buyer in Q4 2022 was Citadel Advisors, an estimated $47.7K added.
Based on aggregated 13F filings for Q4 2022.